Orchid is a cutting-edge whole genome embryo screening with CLIA/CAP-validated performance that reads >99%* of an embryo's genome, compared to the <1% that legacy array technology reads.

Orchid combines Preimplantation Genetic Testing for Aneuploidy (PGT-A) with the ability to screen for hundreds of single gene conditions known to cause severe monogenic disease (such as genetic neurodevelopmental disorders including autism, intellectual disability, developmental delay, epilepsy, genetic birth defects and pediatric and adult-onset hereditary cancers).

This allows Orchid to identify single-gene conditions previously impossible to detect in embryos, and provide superior results compared to traditional tests (cleaner aneuploidy calls, no probes for PGT-M, etc).

All of this is accomplished using the same standard 5–6 cell trophectoderm biopsy used in existing embryo testing, while generating up to 100x more data. With this advanced level of insight, Orchid helps families make more informed decisions for a successful pregnancy and a healthier future.

* Percentage is based on validation studies using genomic regions of National Institute of Standards and Technology - GIAB samples

Whole genome sequencing (WGS) has become a critical tool in identifying single-gene mutations that cause severe conditions.

Geneticists have spent decades identifying single-gene mutations that cause severe conditions. The diagnostic yield, or the percent of cases with a clear genetic cause, ranges by condition but has been increasing over time. For example, 30% of individuals with a neurodevelopmental disorder have an identified single-gene (monogenic) cause.

These advancements are used to diagnose children and adults who present symptoms. Now that whole genome sequencing is possible at the embryo stage, trophectoderm biopsies can be screened for monogenic conditions, and diseases can be identified and avoided before transfer.

This represents a significant advancement over traditional embryo screening (PGT-A), which only focuses on chromosomal analysis.

Orchid's collaboration process is designed to be seamless and straightforward. After an initial orientation, clinicians can easily order tests with Orchid handling all shipping logistics. Using the same 5-6 cell trophectoderm biopsy, Orchid provides comprehensive results and individualized reporting and consultations.

Contact Orchid for an orientation

Sign up for a commitment-free discussion with the Orchid team

Quick and easy ordering

Order tests efficiently, without any added work. Orchid handles shipping logistics for all samples.

Same biopsy, superior results

Get 100x more data and more comprehensive results with the same 5-6 cell trophectoderm biopsy

Individualized reporting and consults

Your patients will receive 1:1 consult with a board certified genetic counselor.

Orchid offers several advantages over existing PGT methodologies. These include faster turnaround times, the ability to detect conditions that other tests may miss, and a comprehensive single screen that includes PGT-A, PGT-M, and gene panels. Moreover, Orchid provides one-on-one genetic counseling for all patients at no additional charge.

Orchid's superior data and hands-on approach can be a valuable addition to any fertility center. Benefits include reducing risk for patients and the practice, providing faster results for a wider variety of patients, and access to Orchid's expert staff. Orchid also provides access to board certified Genetic Counselors and Medical Genetics resources, as needed.

Patients receive comprehensive reports and have access to their own patient portal. Genetic counselors are available to answer both clinician and patient questions.

Orchid adheres to the highest clinical and scientific standards. It works with world-class experts in reproductive medicine and genetics, processes samples in a CAP/CLIA certified laboratory, is licensed to process samples nation-wide (except New York), and its technology has been independently validated.